Use of FDG PET as an Imaging Biomarker in Clinical Trials of Alzheimer’s Disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
PET with the glucose analog FDG as a tracer is a mature and increasingly available clinical imaging technique that can improve the diagnostic accuracy for Alzheimer's disease, which is of particular value at an early stage of the disease when clinical symptoms are still mild and nonspecific. It can also monitor progression of Alzheimer's disease, and the findings are closely related to clinical symptoms. FDG PET, therefore, could also potentially be used as an imaging biomarker for selection of patients and assessment of outcome in clinical trials. Several published intervention studies indicate a good correspondence between clinical outcome and FDG PET findings, but study designs and methods used for data analysis vary widely. Recent developments towards standardization of largely user-independent methods for quantification of regional metabolic impairment on FDG PET scans will allow a new generation of studies that could provide the required evidence for full qualification of FDG PET as an imaging biomarker in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832
Self-citationRELATION BETWEEN PHYSIOLOGICAL FUNCTION AND ENERGY METABOLISM IN THE CENTRAL NERVOUS SYSTEM
Sokoloff, L. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb03919.x · Cited by 807
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550
Cited by
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
van Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“FDG PET has been used as an imaging biomarker for outcome assessment in multiple clinical trials of AD therapeutics (Hoyer, 2002; Landau et al., 2011; Herholz, 2012).”
MethodMitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
“More recently, advanced neuroimaging techniques showed evident metabolic alterations in the brain of AD patients at a very early stage of the disease [44].”
Background
Metadata
- Authors
- Herholz, K.
- Venue
- Biomarkers in Medicine
- Publisher
- Informa UK Limited
- Published
- 2012-08
- Volume
- 6
- Issue
- 4
- Pages
- 431-439
- ISSN
- 1752-0363 (ISSN-L)
- 1752-0371
- OpenAlex
- W1979978322
- Cited by
- 47
- References
- 15
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of FDG PET as an Imaging Biomarker in Clinical Trials of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2217/bmm.12.51
- The paper
- Herholz, K. (2012). Use of FDG PET as an Imaging Biomarker in Clinical Trials of Alzheimer’s Disease. Biomarkers in Medicine. https://doi.org/10.2217/bmm.12.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.